Chronic antipsychotic treatment selectively alters nerve growth factor and neuropeptide Y immunoreactivity and the distribution of choline acetyl transferase in rat brain regions

The International Journal of Neuropsychopharmacology
Francesco AngelucciA A Mathé

Abstract

Neuropeptides and neurotrophins play a number of roles in the central nervous system (CNS). Nerve growth factor (NGF), the first characterized member of the family of neurotrophins, influences the synthesis of some neuropeptides, including neuropeptide Y (NPY), a peptide amply expressed in the CNS, interacting with catecholamines and modifying behaviour. In this study we investigated whether antipsychotic treatment affects the constitutive levels of NGF-, NPY- and choline acetyl transferase (ChAT)-like immunoreactivities (-LI) in the CNS. Rats were fed food supplemented with haloperidol (1.15 mg/100 g food), risperidone (1.15 or 2.3 mg/100 g food), or vehicle. After 29 d treatment animals were sacrificed with focused high-energy microwave irradiation for radioimmunoassay (RIA) of NPY-LI, by decapitation for analysis of NGF, and by perfusion for immunocytochemistry. Haloperidol and risperidone elevated NGF-LI concentrations in the hypothalamus but decreased NGF-LI in the striatum and hippocampus. In contrast, antipsychotics did not alter NPY-LI in the striatum. Haloperidol increased NPY-LI concentration in the occipital cortex, while risperidone increased NPY-LI in the occipital cortex, hippocampus, and hypothalamus. Significant...Continue Reading

Citations

Mar 28, 2008·Neurotoxicity Research·Márcio R MartinsJoão Quevedo
Dec 21, 2010·Psychopharmacology·Parichehr Hassanzadeh, Sina Rahimpour
Apr 12, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Gal Shoval, Abraham Weizman
Sep 7, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Anilkumar PillaiSahebarao P Mahadik
Feb 15, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Parichehr Hassanzadeh, Anna Hassanzadeh
Feb 2, 2010·Journal of Psychiatric Research·Renan P SouzaAlbert H C Wong
Sep 2, 2009·Progress in Neuro-psychopharmacology & Biological Psychiatry·Mei Hong XiuXiang Yang Zhang
Sep 13, 2008·Journal of Neurochemistry·Anilkumar PillaiSahebarao P Mahadik
Apr 12, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Francesco AngelucciAleksander A Mathé
Nov 9, 2004·Neuroscience Letters·Adalisa ReinkeJoão Quevedo
May 26, 2007·Schizophrenia Research·Peter F BuckleyAlvin Terry
Jan 12, 2010·The International Journal of Neuropsychopharmacology·Alvin V TerryMichael G Bartlett
Jan 19, 2005·Molecular Psychiatry·F AngelucciA A Mathé
Aug 18, 2006·Behavioural Pharmacology·Benício N FreyFlávio Kapczinski
Aug 13, 2003·Journal of Neurochemistry·M M KhanS P Mahadik
Feb 18, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Alvin V TerrySahebarao P Mahadik
Dec 3, 2011·CNS Drugs·James L RoerigJames E Mitchell
Aug 26, 2021·Neuroscience Letters·Eliyahu DremencovSaak V Ovsepian

❮ Previous
Next ❯

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.